Executive Summary

International travel for FDA employees should be restricted to "essential" meetings in these non-"routine" times, Commissioner McClellan clarifies in March 24 memo. "Examples of 'essential' would include meetings where significant regulatory policy decisions will be made that will impact the Agency directly and where the policy decision would be expected to be different were FDA personnel not there to represent the Agency's position. 'Essential' does not include routine attendance at a conference, routine speeches, outreach, training, routine meetings of working groups, etc.," the memo says...